Cases & Deals

Wellington Partners invests in Genticel

Clients Wellington Partners Advisory AG

Jones Day advised Wellington Partners Advisory AG in connection with its purchase of €4 million of Series C Preferred Stock in an €18.2 million private placement by Genticel, a developer of therapeutic vaccines against HPV infection with high-risk types. The remaining €14.2 million was provided by existing shareholders EdRIP, IDInvest, InnoBio, IRDI, and Amundi.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.